Australian company, Vaxine Pty Ltd, has developed a protein based COVID-19 vaccine that completely blocks virus transmission to non-immune individuals. The COVAX-19™ vaccine being developed by Australian company, Vaxine Pty Ltd, is set to be a game-changer in the fight against the COVID-19 pandemic and could allow earlier re-opening of national borders after it was shown to not only protect but also to completely block virus transmission to non-immune animals.
Vaxine’s biggest challenge now is to quickly raise the financial resources to complete Phase 3 human clinical trials and get Covid-19 vaccine manufactured at large scale which is likely to be in the order of $50 million dollars.
In another major breakthrough, Vaxine have also successfully created a breakthrough multivalent vaccine to protect against the new Covid-19 virus variants including the worrying South African, Brazilian and Indian mutant strains. The results of this multivalent Covid-19 vaccine formulation in animal testing is looking very promising.
Vaxine’s COVAX-19™ vaccine is a subunit vaccine based on synthetic protein produced using harmless insect cells to which Vaxine’s proprietary Advax polysaccharide adjuvant is added as a vaccine turbocharger to maximise the vaccine’s effectiveness and durability.
Vaxine is currently working with partners in overseas countries to assist in the upcoming phase 3 human clinical trials.
Vaxine has a long history of successfully developing pandemic vaccines, having previously developed vaccines against the SARS 3 and MERS coronaviruses that were shown to be highly protective in relevant animal models.
The United States has been pushing India to restart vaccine exports as it looks to stem the global spread of the Covid pandemic.
Quess Corp, India’s leading business services provider, announced the launch of its new healthcare vertical to address the shortage of healthcare professionals.
The shippers are in for struggle yet another time, with the market buzzing in speculations of liners planning of ‘blank sailing’ during China’s Golden Week holiday in early October to extract maximised profits.
Less than a month into a COVID-19 vaccine booster drive, Israel is seeing signs of an impact on the country’s high infection and severe illness rates fuelled by the fast-spreading delta variant, officials and scientists say.
Researchers have developed a blood test able to detect more than 50 types of cancer that is accurate enough to be used nationally as a multi-cancer screening test in those at higher risk of the disease, including those aged over 50 with no symptoms.
At Last: Separated and Freshly Bound –
Amidation of light alkanes
AstraZeneca (AZ) has announced that new real-world data from Canada shows its COVID-19 vaccine – Vaxzevria – was found to be highly effective after one dose against severe disease or hospitalisation caused by the Beta and Delta variants.
Interruptions to the inspection programme of the European Directorate for the Quality of Medicines & HealthCare (EDQM) due to travel restrictions – made necessary by the COVID-19 pandemic – led to the creation of a system of Real-Time Remote Inspections (RTEMIS).